ARTICLE | Company News
EC approves Latuda for schizophrenia
March 28, 2014 11:58 PM UTC
The European Commission approved an MAA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for Latuda lurasidone to treat schizophrenia in adults. Takeda has exclusive rights from Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506) to develop and commercialize the once-daily oral product for schizophrenia and bipolar disorder in the EU, Norway, Russia, Switzerland and Turkey. ...